In addition, we expect that the reduction of neonatal morbidity associated with oxytocin discontinuation will be associated with a reduction in maternal morbidity, in particular due to a reduction of postpartum hemorrhage which remains the leading cause of postpartum maternal morbidity. This evidence concerns the gene OXT and postpartum hemorrhage.